ClinicalTrials.gg
CompletedNCT01895946OAKUpdated May 25, 2016Results posted

Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and Tolerability

A Phase 1 interventional study of AZD5363 and AZD5363 in Advanced Solid Malignancy,, Safety and Tolerability, and Pharmacokinetics, Pharmacodynamics,, sponsored by AstraZeneca. Completed at 3 sites in 2 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2016-05-25.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
18 Years to 100 Years
Sex
All
01

Study summary

Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and Tolerability

Read the detailed description

This study is designed to investigate the safety, tolerability and pharmacokinetics of a new drug, AZD5363, in patients with advanced cancer . This study will investigate how the body handles AZD5363 (ie, how quickly the body absorbs and removes the drug), the comparison of a capsule and a tablet formulation and the effect of food on AZD5363 tablet formulation.

02

Conditions studied

  • Advanced Solid Malignancy,
  • Safety and Tolerability,
  • Pharmacokinetics, Pharmacodynamics,
  • Tumour Response,

Keywords

  • Advanced solid malignancy, AZD5363,
  • food effect,
  • formulation comparison
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: -

  • Aged at least 18 years
  • The presence of a solid, malignant tumour, excluding lymphoma, that is resistance to standard therapies or for which no standard therapies exist
  • The presence of at least one lesion that can be accurately assessed at baseline by Computerised Tomography (CT), Magnetic Resonance Imaging (MRI) or plain X-ray and is suitable for repeated assessment
  • Estimated of more than 12 weeks

Exclusion Criteria: -

  • abnormalities of glucose metabolism
  • Spinal cord compression or unless asymptomatic, treated and stable (not requiring )
  • Evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses or active infections including , C and (HIV)
  • Evidence of clinically significant cardiac abnormalities, uncontrolled hypotension, below the lower limit of normal for the site or experience of significant cardiac interventional procedures
  • A bad reaction to AZD5363 or any drugs similar to it in structure or class
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Part A: Formulation Switch

    AZD5363 tablet twice daily followed by AZD5363 capsule twice daily on an intermittent regimen (4 days on, 3 days off).

    Drug: AZD5363

  • Experimental
    Part B: Food effect

    AZD5363 tablet twice daily on an intermittent regimen (4 days on, 3 days off) with/without food on one occasion

    Drug: AZD5363

Interventions

  • Oral AZD5363 twice daily, 4 days on 3 days off: tablet formulation for one week, followed by two weeks with capsule formulation.

  • Oral AZD5363 twice daily, 4 days on 3 days off, tablet formulation. On day 4 AZD5363 tablet without food. On day 11 AZD5363 tablet with food.

06

What researchers measure

Primary outcomes

  1. Ratio of Css,Max for Day 4 to Day 11

    The actual sampling times were used in the pharmacokinetics (PK) parameter calculations and PK parameters were derived using standard non-compartmental methods. Following the twice daily dosing in Cycle 1 at Day 4 and 11 for both the formulation switch and food effect investigations, the following PK parameters have been determined: Maximum plasma concentration at steady state (Css max), time to Css,max (tss max), minimum plasma concentration at steady state (Css min), area under the plasma concentration-time curve from zero to the end of the dosing interval (AUCss) and apparent clearance (CLss/F). Css max, tss max were determined by inspection of the concentration-time profiles. AUCss was calculated using the linear up / log down trapezoidal rule. CLss/F was determined from the ratio of dose/AUCss. Ratio of Css,max for Day 4 to Day 11 have been derived.

    Time frame: Day 4 and Day 11

  2. Ratio of AUCss for Day 4 to Day 11

    The actual sampling times were used in the parameter calculations and PK parameters were derived using standard non-compartmental methods. Following the twice daily dosing in Cycle 1 at Day 4 and 11 for both the formulation switch and food effect investigations, the following PK parameters have been determined: Css max, tss max, Css min, area under the plasma concentration-time curve from zero to the end of the dosing interval (AUCss) and CLss/F. Css max, tss max were determined by inspection of the concentration-time profiles. AUCss was calculated using the linear up / log down trapezoidal rule. CLss/F was determined from the ratio of dose/AUCss. Ratio of AUCss for Day 4 to Day 11 have been derived.

    Time frame: Day 4 and Day 11

Secondary outcomes

  1. Efficacy: Best Objective Response (BOR)

    Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 guidelines for measurable, non-measurable, target lesions (TLs) and non-target lesions (NTLs) and the objective tumour response criteria was used. Categorisation of objective tumour response assessment was based on the RECIST 1.1 guidelines for response: CR (complete response, efined as disappearance of all target lesions), PR (partial response, defined as \>=30% decrease in the sum of the longest diameter of target lesions), SD (stable disease, defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression) and PD (progression of disease, defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a nontarget lesion). BOR was the best overall response observed across the study and up to 36 weeks. Number of subjects with response (CR or PR) is described.

    Time frame: Assessed every 6 weeks, up to 36 weeks

  2. Efficacy: Disease Control at Week 12

    Disease control = confirmed complete response + confirmed partial response + stable disease at 12 weeks

    Time frame: Week 12

  3. Efficacy: Target Lesion Size, Percentage Change From Baseline at Week 12

    Tumour size is the sum of the longest diameters of the target lesions. Target lesions are measurable tumour lesions. The percentage change in target lesion tumour size at each week 12 for which data are available was obtained for each subject taking the difference between the sum of the target lesion at each week 12 and the sum of the target lesions at baseline divided by the sum of the target lesions at baseline multiplied by 100 (i.e. (week 12) - baseline)/baseline \* 100).

    Time frame: Week 12

  4. Efficacy: Target Lesion Size, Best Percentage Change From Baseline

    Tumour size is the sum of the longest diameters of the target lesions. Target lesions are measurable tumour lesions. best percentage change in tumour size from baseline is the maximum reduction from baseline or the minimum increase from baseline in the absence of a reduction from baseline based on all post baseline assessments.

    Time frame: Assessed every 6 weeks up to 36 weeks

  5. Efficacy: Progression-free Survival (PFS)

    PFS is defined as the time from randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the subject withdraws from randomised therapy or receives another anti-cancer therapy prior to progression. Subjects who have not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST assessment. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a nontarget lesion, or the appearance of new lesions.

    Time frame: Assessed every 6 weeks up to 36 weeks

07

Results

Posted May 25, 2016
Limitations and caveats
Small numbers of patients in the first (fasted) and second (fed) treatment periods overall make interpretation difficult.

Participant flow

There were 2 parts to this study: Part A (tablet formulation assessment) followed by Part B (food effect assessment). Part A: first patient enrolled on 18/12/2013 and last patient completed on 16/12/2014. Part B: first patient enrolled on 10/09/2014 and last patient completed on 22/07/2015. Part A was conducted at 3 sites and Part B at 2 sites.

Participant flow — Overall Study
MilestonePart APart B
Started1812
Completed1812
Not completed00

Outcome measures

PrimaryRatio of Css,Max for Day 4 to Day 11

The actual sampling times were used in the pharmacokinetics (PK) parameter calculations and PK parameters were derived using standard non-compartmental methods. Following the twice daily dosing in Cycle 1 at Day 4 and 11 for both the formulation switch and food effect investigations, the following PK parameters have been determined: Maximum plasma concentration at steady state (Css max), time to Css,max (tss max), minimum plasma concentration at steady state (Css min), area under the plasma concentration-time curve from zero to the end of the dosing interval (AUCss) and apparent clearance (CLss/F). Css max, tss max were determined by inspection of the concentration-time profiles. AUCss was calculated using the linear up / log down trapezoidal rule. CLss/F was determined from the ratio of dose/AUCss. Ratio of Css,max for Day 4 to Day 11 have been derived.

Time frame:
Day 4 and Day 11
Reported as:
Geometric mean · Ratio
Ratio of Css,Max for Day 4 to Day 11
RatioPart APart B
Ratio of Css,Max for Day 4 to Day 111.02 (0.86 to 1.20)0.67 (0.55 to 0.82)
Statistical analysis
  • Part A · Mixed Models Analysis · Least square mean difference (lsm): 1.02 · 90% CI 0.86 to 1.20
  • Part B · Mixed Models Analysis · Least square means difference (lsm): 0.67 · 90% CI 0.55 to 0.82
PrimaryRatio of AUCss for Day 4 to Day 11

The actual sampling times were used in the parameter calculations and PK parameters were derived using standard non-compartmental methods. Following the twice daily dosing in Cycle 1 at Day 4 and 11 for both the formulation switch and food effect investigations, the following PK parameters have been determined: Css max, tss max, Css min, area under the plasma concentration-time curve from zero to the end of the dosing interval (AUCss) and CLss/F. Css max, tss max were determined by inspection of the concentration-time profiles. AUCss was calculated using the linear up / log down trapezoidal rule. CLss/F was determined from the ratio of dose/AUCss. Ratio of AUCss for Day 4 to Day 11 have been derived.

Time frame:
Day 4 and Day 11
Reported as:
Geometric mean · Ratio
Ratio of AUCss for Day 4 to Day 11
RatioPart APart B
Ratio of AUCss for Day 4 to Day 110.90 (0.77 to 1.06)0.89 (0.76 to 1.05)
Statistical analysis
  • Part A · Mixed Models Analysis · Least square means difference (lsm): 0.90 · 90% CI 0.77 to 1.06
  • Part B · Mixed Models Analysis · Least square means difference (lsm): 0.89 · 90% CI 0.76 to 1.05
SecondaryEfficacy: Best Objective Response (BOR)

Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 guidelines for measurable, non-measurable, target lesions (TLs) and non-target lesions (NTLs) and the objective tumour response criteria was used. Categorisation of objective tumour response assessment was based on the RECIST 1.1 guidelines for response: CR (complete response, efined as disappearance of all target lesions), PR (partial response, defined as \>=30% decrease in the sum of the longest diameter of target lesions), SD (stable disease, defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression) and PD (progression of disease, defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a nontarget lesion). BOR was the best overall response observed across the study and up to 36 weeks. Number of subjects with response (CR or PR) is described.

Time frame:
Assessed every 6 weeks, up to 36 weeks
Reported as:
Number · Participants
Efficacy: Best Objective Response (BOR)
ParticipantsPart APart B
Efficacy: Best Objective Response (BOR)00
SecondaryEfficacy: Disease Control at Week 12

Disease control = confirmed complete response + confirmed partial response + stable disease at 12 weeks

Time frame:
Week 12
Reported as:
Number · Participants
Efficacy: Disease Control at Week 12
ParticipantsPart APart B
Efficacy: Disease Control at Week 1213
SecondaryEfficacy: Target Lesion Size, Percentage Change From Baseline at Week 12

Tumour size is the sum of the longest diameters of the target lesions. Target lesions are measurable tumour lesions. The percentage change in target lesion tumour size at each week 12 for which data are available was obtained for each subject taking the difference between the sum of the target lesion at each week 12 and the sum of the target lesions at baseline divided by the sum of the target lesions at baseline multiplied by 100 (i.e. (week 12) - baseline)/baseline \* 100).

Time frame:
Week 12
Reported as:
Mean · Percentage change from baseline
Efficacy: Target Lesion Size, Percentage Change From Baseline at Week 12
Percentage change from baselinePart APart B
Efficacy: Target Lesion Size, Percentage Change From Baseline at Week 128.1 ± 14.72-1.5 ± 6.49
SecondaryEfficacy: Target Lesion Size, Best Percentage Change From Baseline

Tumour size is the sum of the longest diameters of the target lesions. Target lesions are measurable tumour lesions. best percentage change in tumour size from baseline is the maximum reduction from baseline or the minimum increase from baseline in the absence of a reduction from baseline based on all post baseline assessments.

Time frame:
Assessed every 6 weeks up to 36 weeks
Reported as:
Mean · Percentage change from baseline
Efficacy: Target Lesion Size, Best Percentage Change From Baseline
Percentage change from baselinePart APart B
Efficacy: Target Lesion Size, Best Percentage Change From Baseline10.5 ± 13.620.2 ± 9.92
SecondaryEfficacy: Progression-free Survival (PFS)

PFS is defined as the time from randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the subject withdraws from randomised therapy or receives another anti-cancer therapy prior to progression. Subjects who have not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST assessment. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a nontarget lesion, or the appearance of new lesions.

Time frame:
Assessed every 6 weeks up to 36 weeks
Reported as:
Median · weeks
Efficacy: Progression-free Survival (PFS)
weeksPart APart B
Efficacy: Progression-free Survival (PFS)6.1 ± 13.6213.7 ± 9.92

Adverse events

Collected over Adverse events with an onset date on or after the date of first dose and up to and including 28 days following the date of last dose of study medication were collected.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A—5/18 (27.8%)18/18 (100%)
Part B—6/12 (50%)12/12 (100%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventPart APart B
DiarrhoeaGastrointestinal disorders1/183/12
Rash maculo-papularSkin and subcutaneous tissue disorders0/182/12
Pneumonia mycoplasmalInfections and infestations0/181/12
HyperglycaemiaMetabolism and nutrition disorders0/181/12
VomitingGastrointestinal disorders1/181/12
StomatitisGastrointestinal disorders0/181/12
DyspnoeaRespiratory, thoracic and mediastinal disorders0/181/12
Rash papularSkin and subcutaneous tissue disorders1/181/12
PyrexiaGeneral disorders1/180/12
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/180/12
Most frequent other events
Showing 10 of 106
Most frequent other events
EventPart APart B
DiarrhoeaGastrointestinal disorders14/189/12
FatigueGeneral disorders7/188/12
NauseaGastrointestinal disorders8/188/12
HyperglycaemiaMetabolism and nutrition disorders10/186/12
Dry skinSkin and subcutaneous tissue disorders4/185/12
VomitingGastrointestinal disorders5/185/12
PyrexiaGeneral disorders2/183/12
Respiratory tract infectionInfections and infestations0/183/12
AnaemiaBlood and lymphatic system disorders4/182/12
Decreased appetiteMetabolism and nutrition disorders4/182/12

Baseline characteristics

Age, Customized
Age, Customized(Participants)Part APart BTotal
<50 years415
Between 50 and 65 years9615
>=65 years5510
Sex: Female, Male
Sex: Female, Male(Participants)Part APart BTotal
Female8715
Male10515
08

Study locations

3 sites
  • Research Site
    Amsterdam, 1066 CX, Netherlands
  • Research Site
    Manchester, M20 4BX, United Kingdom
  • Research Site
    Surrey, SM2 5PT, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Feb 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2013
First posted
Jul 11, 2013
Start
Dec 2013
Primary completionActual
Feb 2015
CompletionActual
Jul 2015
Results first posted
May 25, 2016
Last update
May 25, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01895946
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 11, 2013
Start date
Dec 2013
Primary completion
Feb 2015
Completion
Jul 2015
Results posted
May 25, 2016
Last update
May 25, 2016

Study contacts

Justin Lindemann, MSD
study director · AstraZeneca
Udai Banerji, MD, PhD
principal investigator · Institute of Cancer Research, United Kingdom

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Capivasertib

Start the discussion